300158.SHE Shanxi Zhendong Pharmaceutical
- Market cap
- CNY 4.58B
- P/E
- -
- P/B
- 1.44x
- ROE
- -10.0%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is 300158.SHE undervalued?
Graham numberThe Graham number of Shanxi Zhendong Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanxi Zhendong Pharmaceutical fundamental analysis
No fundamental analysis for Shanxi Zhendong Pharmaceutical yet.
Shanxi Zhendong Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, researches, develops, produces, and sells pharmaceutical drugs in China. The company offers drugs for oncology, dermatology, digestive, urological, and cardiovascular diseases, as well as seeds. It is also involved in the integrating seeds, seedling cultivation, planting, processing, storage; and provision of Chinese medicinal materials and processed medicinal slices. In addition, the company engages in …
Full company profileShanxi Zhendong Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanxi Zhendong Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.26B | 3.28B | 3.73B | 3.42B | 4.40B | 4.85B | 5.09B | 3.73B | 3.63B | 2.97B | 1.74B |
| Gross Profit | 1.02B | 1.46B | 2.15B | 2.24B | 2.84B | 3.02B | 3.04B | 1.83B | 1.80B | 1.16B | 834M |
| Operating Income | 42.8M | 207M | 361M | -83.9M | 191M | 326M | 3.12B | -5.92M | -30.0M | -715M | -313M |
| EBITDA | 191M | 379M | 493M | 57.1M | 335M | 511M | 3.26B | 135M | 85.2M | -1.20B | -285M |
| Net Income | 64.6M | 203M | 302M | -147M | 143M | 262M | 2.62B | -51.3M | -44.0M | -1.33B | -319M |
| EPS | 0.11 | 0.28 | 0.29 | -0.14 | 0.14 | 0.26 | 2.55 | -0.05 | -0.04 | -1.30 | -0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 4.07B | 6.87B | 7.61B | 7.21B | 6.92B | 7.60B | 10.1B | 6.55B | 6.18B | 4.98B | 4.19B |
| Total Liabilities | 2.04B | 1.60B | 2.06B | 1.85B | 1.47B | 1.97B | 2.04B | 1.33B | 1.04B | 1.32B | 1.05B |
| Shareholders' Equity | 1.99B | 5.25B | 5.54B | 5.36B | 5.44B | 5.64B | 8.08B | 5.25B | 5.18B | 3.70B | 3.18B |
| Cash & Short-term Investments | 310M | 657M | 658M | 787M | 526M | 926M | 5.69B | 2.74B | 2.25B | 1.57B | 350M |
| Total Debt | 650M | 319M | 447M | 408M | 54.0M | 415M | 313M | 21.9M | 1.63M | 39.2M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 152M | -44.7M | 45.1M | 154M | 186M | 222M | 284M | 86.3M | -190M | -150M | - |
| Capital Expenditure | 46.9M | 147M | 47.9M | 23.9M | 19.4M | 184M | 152M | 146M | 116M | 298M | 151M |
| Free Cash Flow | 105M | -192M | -2.85M | 131M | 167M | 38.0M | 133M | -59.5M | -365M | -448M | -61.6M |
| Ratios | |||||||||||
| ROE | 3.2% | 3.9% | 5.4% | -2.8% | 2.6% | 4.6% | 32.4% | -1.0% | -0.8% | -35.9% | -10.0% |
| ROA | 1.6% | 3.0% | 4.0% | -2.0% | 2.1% | 3.4% | 25.9% | -0.8% | -0.7% | -26.7% | -7.6% |
| Net Profit Margin | 2.9% | 6.2% | 8.1% | -4.3% | 3.2% | 5.4% | 51.4% | -1.4% | -1.2% | -44.7% | -18.3% |
| Debt to Equity | 0.33x | 0.06x | 0.08x | 0.08x | 0.01x | 0.07x | 0.04x | 0.00x | 0.00x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanxi Zhendong Pharmaceutical dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 9, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 585K | 0.00 | - |
| 2023 | CNY 1.22M | 0.00 | - |
| 2022 | CNY 2.77B | 2.70 | - |
| 2021 | CNY 175M | 0.17 | 6.7% |
| 2020 | CNY 51.4M | 0.05 | 19.6% |
| 2019 | CNY 18.7M | 0.02 | 13.1% |
| 2018 | CNY 53.9M | 0.05 | - |
| 2017 | CNY 49.3M | 0.05 | 16.3% |
| 2016 | CNY 200M | 0.27 | 98.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 14, 2018.
Who owns Shanxi Zhendong Pharmaceutical
- Insiders 41.09%
- Institutions 0.13%
- Public & others 58.78%
- Shares outstanding 992M
- Free float 658M
Shanxi Zhendong Pharmaceutical company profile
- Company name
- Shanxi Zhendong Pharmaceutical
- Ticker
- 300158.SHE
- ISIN
- CNE100000YR9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,695
- Fiscal year end
- December
- Address
- Zhendong Science and Technology Park, Changzhi, China, 047100
- Phone
- 86 35 5809 6012
- Website
- zdjt.com
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, researches, develops, produces, and sells pharmaceutical drugs in China. The company offers drugs for oncology, dermatology, digestive, urological, and cardiovascular diseases, as well as seeds. It is also involved in the integrating seeds, seedling cultivation, planting, processing, storage; and provision of Chinese medicinal materials and processed medicinal slices. In addition, the company engages in the production of anti-tumor raw materials, small-volume injections, lyophilized powder injections, tablets, hard capsules. granules, and powders. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is headquartered in Changzhi, China.
Shanxi Zhendong Pharmaceutical management
3- Mr. Xufeng WangVP & Director · born 1982
- Ms. Rongli YouVice President of R&D · born 1979
- Mr. Rui WangPresident · born 1976